279 related articles for article (PubMed ID: 28844295)
1. Concentrations in plasma clozapine levels in schizophrenic and schizoaffective patients.
Iglesias García C; Iglesias Alonso A; Bobes J
Rev Psiquiatr Salud Ment; 2017; 10(4):192-196. PubMed ID: 28844295
[TBL] [Abstract][Full Text] [Related]
2. ABCB1 polymorphisms are associated with clozapine plasma levels in psychotic patients.
Consoli G; Lastella M; Ciapparelli A; Catena Dell'Osso M; Ciofi L; Guidotti E; Danesi R; Dell'Osso L; Del Tacca M; Di Paolo A
Pharmacogenomics; 2009 Aug; 10(8):1267-76. PubMed ID: 19663671
[TBL] [Abstract][Full Text] [Related]
3. Clinical predictors of serum clozapine levels in patients with treatment-resistant schizophrenia.
Rajkumar AP; Poonkuzhali B; Kuruvilla A; Jacob M; Jacob KS
Int Clin Psychopharmacol; 2013 Jan; 28(1):50-6. PubMed ID: 23104241
[TBL] [Abstract][Full Text] [Related]
4. Relationship between plasma concentrations of clozapine and norclozapine and therapeutic response in patients with schizophrenia resistant to conventional neuroleptics.
Spina E; Avenoso A; Facciolà G; Scordo MG; Ancione M; Madia AG; Ventimiglia A; Perucca E
Psychopharmacology (Berl); 2000 Jan; 148(1):83-9. PubMed ID: 10663421
[TBL] [Abstract][Full Text] [Related]
5. Intra-individual variation of clozapine and norclozapine plasma levels in clinical practice.
Turrion MC; Perez J; Bernardo M; Fernandez-Egea E
Rev Psiquiatr Salud Ment (Engl Ed); 2020; 13(1):31-35. PubMed ID: 31122757
[TBL] [Abstract][Full Text] [Related]
6. Plasma ratio of clozapine to N-desmethylclozapine can predict cognitive performance in treatment-resistant psychotic patients.
Molins C; Carceller-Sindreu M; Navarro H; Carmona C; Piñeiro M; Martínez E; Álvarez E; Portella MJ
Psychiatry Res; 2017 Dec; 258():153-157. PubMed ID: 29024893
[TBL] [Abstract][Full Text] [Related]
7. [Clozapine-resistant schizophrenia related to an increased metabolism and benefit of fluvoxamine: four case reports].
Papetti F; Morel-Pingault V; Buisse V; Maziere L; Banayan M; Thauby S; Besnard T; Darcourt G; Pringuey D
Encephale; 2007 Oct; 33(5):811-8. PubMed ID: 18357853
[TBL] [Abstract][Full Text] [Related]
8. CYP1A2 activity as measured by a caffeine test predicts clozapine and active metabolite steady-state concentrationin patients with schizophrenia.
Ozdemir V; Kalow W; Posner P; Collins EJ; Kennedy JL; Tang BK; Albers LJ; Reist C; Roy R; Walkes W; Afra P
J Clin Psychopharmacol; 2001 Aug; 21(4):398-407. PubMed ID: 11476124
[TBL] [Abstract][Full Text] [Related]
9. Plasma clozapine levels and clinical response for treatment-refractory schizophrenic patients.
Kronig MH; Munne RA; Szymanski S; Safferman AZ; Pollack S; Cooper T; Kane JM; Lieberman JA
Am J Psychiatry; 1995 Feb; 152(2):179-82. PubMed ID: 7840349
[TBL] [Abstract][Full Text] [Related]
10. Once-daily versus divided dosing regimens of clozapine: A cross-sectional study in Singapore.
Yang Z; Takeuchi H; Yee JY; See YM; Tang C; Ng BT; Lee J
Schizophr Res; 2024 Jun; 268():66-73. PubMed ID: 37833207
[TBL] [Abstract][Full Text] [Related]
11. The clinical use of plasma clozapine levels.
Bell R; McLaren A; Galanos J; Copolov D
Aust N Z J Psychiatry; 1998 Aug; 32(4):567-74. PubMed ID: 9711372
[TBL] [Abstract][Full Text] [Related]
12. Clozapine and norclozapine concentrations in serum and plasma samples from schizophrenic patients.
Hermida J; Paz E; Tutor JC
Ther Drug Monit; 2008 Feb; 30(1):41-5. PubMed ID: 18223461
[TBL] [Abstract][Full Text] [Related]
13. Long-term pharmacokinetics of clozapine.
Kurz M; Hummer M; Kemmler G; Kurzthaler I; Saria A; Fleischhacker WW
Br J Psychiatry; 1998 Oct; 173():341-4. PubMed ID: 9926040
[TBL] [Abstract][Full Text] [Related]
14. Plasma clozapine and norclozapine in relation to prescribed dose and other factors in patients aged <18 years: data from a therapeutic drug monitoring service, 1994-2010.
Couchman L; Bowskill SV; Handley S; Patel MX; Flanagan RJ
Early Interv Psychiatry; 2013 May; 7(2):122-30. PubMed ID: 22747759
[TBL] [Abstract][Full Text] [Related]
15. Plasma levels of clozapine and norclozapine in Mexican schizophrenia patients.
González-Esquivel DF; Castro N; Ramírez-Bermúdez J; Custodio V; Rojas-Tomé S; Castro-Román R; Jung-Cook H
Arzneimittelforschung; 2011; 61(6):335-9. PubMed ID: 21827043
[TBL] [Abstract][Full Text] [Related]
16. The effect of variable cigarette consumption on the interaction with clozapine and olanzapine.
Haslemo T; Eikeseth PH; Tanum L; Molden E; Refsum H
Eur J Clin Pharmacol; 2006 Dec; 62(12):1049-53. PubMed ID: 17089108
[TBL] [Abstract][Full Text] [Related]
17. Clozapine: in prevention of suicide in patients with schizophrenia or schizoaffective disorder.
Wagstaff A; Perry C
CNS Drugs; 2003; 17(4):273-80; discussion 281-3. PubMed ID: 12665398
[TBL] [Abstract][Full Text] [Related]
18. Risperidone augmentation of clozapine: a critical review.
Kontaxakis VP; Ferentinos PP; Havaki-Kontaxaki BJ; Paplos KG; Pappa DA; Christodoulou GN
Eur Arch Psychiatry Clin Neurosci; 2006 Sep; 256(6):350-5. PubMed ID: 16900439
[TBL] [Abstract][Full Text] [Related]
19. Clozapine serum concentrations in dopamimetic psychosis in Parkinson's disease and related disorders.
Lutz UC; Sirfy A; Wiatr G; Altpass D; Farger G; Gasser T; Karle KN; Batra A
Eur J Clin Pharmacol; 2014 Dec; 70(12):1471-6. PubMed ID: 25323805
[TBL] [Abstract][Full Text] [Related]
20. Effects of clozapine on substance use in patients with schizophrenia and schizoaffective disorder: a retrospective survey.
Zimmet SV; Strous RD; Burgess ES; Kohnstamm S; Green AI
J Clin Psychopharmacol; 2000 Feb; 20(1):94-8. PubMed ID: 10653215
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
